Why fake news is bad for business
By Rose Jacobs – Many social-media websites struggle to maximize user engagement while minimizing the amount of misinformation shared and re-shared. The stakes are high for Facebook, Twitter, and their rivals, which generate most of their revenue from advertising. Viral content leads to higher user engagement, which in turn leads to more advertising revenue.
But content-management algorithms designed to maximize user engagement may inadvertently promote content of dubious quality—including fake news.
The researchers’ models assume platform operators can tell the difference between factual and fictitious posts. They demonstrate that engagement levels fall when users aren’t warned of posts that contain misinformation—to levels lower than when users are discouraged from clicking on the dubious material.
A limitation of the research is the models’ assumption that the people using social networks and the algorithms running them know whether posts are true, false, or shaded somewhere in between. more>
Industrial Medicine: Cell Therapy Scales Up
By Maggie Sieger – Cell therapy is a new way to treat serious diseases like cancer by extracting living cells from a donor or a patient, changing them so they can recognize and attack diseased cells or deliver treatment, and returning them to the patient’s body. But manufacturing the cells is a costly and time-consuming endeavor. A single dose can cost hundreds of thousands of dollars to make.
That’s because in the more than 900 ongoing regenerative medicine trials worldwide — a 19 percent jump since 2016 — researchers generally manufacture each patient’s dose of bio-engineered cells by hand. The individualized nature of cell therapy makes it not only prohibitively pricey, but also difficult to scale into commercial production.
That hasn’t been a problem while cell therapy was still confined to research labs. But as medical science advances and regulators approve a growing numbers of modified cell therapies for general use, handcrafting doses won’t be enough. “It’s relatively easy to do 15 or 20 doses by hand, but it’s nearly impossible to efficiently make thousands,” says GE Healthcare’s Aaron Dulgar-Tulloch, director of cell therapy research and development at the Centre for Advanced Therapeutic Cell Technologies (CATCT) in Toronto.
One way to speed the process is GE Healthcare’s FlexFactory for cell therapy. Cellular Biomedicine Group Inc. (CBMG) will be the first company to install this closed, semi-automated system for manufacturing bio-engineered cells in its Shanghai plant and use it to create cell therapies to treat various blood and solid tumor cancers. more>
Posted in Business, Economic development, Economy, Education, Healthcare, Nature, Science, Technology
Tagged Business improvement, Cancer, Cell therapy, GE, Health, Manufacturing